- Home
- QURE vs ABUS Comparison
QURE vs ABUS Comparison
Compare QURE & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- ABUS
- Stock Information
- Founded
- QURE 1998
- ABUS 2005
- Country
- QURE Netherlands
- ABUS United States
- Employees
- QURE N/A
- ABUS N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- QURE Health Care
- ABUS Health Care
- Exchange
- QURE Nasdaq
- ABUS Nasdaq
- Market Cap
- QURE 866.3M
- ABUS 711.2M
- IPO Year
- QURE 2007
- ABUS N/A
- Fundamental
- Price
- QURE $14.16
- ABUS $4.43
- Analyst Decision
- QURE Strong Buy
- ABUS Strong Buy
- Analyst Count
- QURE 11
- ABUS 2
- Target Price
- QURE $39.91
- ABUS $5.00
- AVG Volume (30 Days)
- QURE 1.1M
- ABUS 1.6M
- Earning Date
- QURE 11-04-2025
- ABUS 11-05-2025
- Dividend Yield
- QURE N/A
- ABUS N/A
- EPS Growth
- QURE N/A
- ABUS N/A
- EPS
- QURE N/A
- ABUS N/A
- Revenue
- QURE $14,337,000.00
- ABUS $15,416,000.00
- Revenue This Year
- QURE N/A
- ABUS $138.02
- Revenue Next Year
- QURE $288.08
- ABUS N/A
- P/E Ratio
- QURE N/A
- ABUS N/A
- Revenue Growth
- QURE N/A
- ABUS 53.23
- 52 Week Low
- QURE $4.45
- ABUS $2.71
- 52 Week High
- QURE $19.18
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- QURE 34.28
- ABUS 63.83
- Support Level
- QURE $17.03
- ABUS $4.37
- Resistance Level
- QURE $17.76
- ABUS $5.10
- Average True Range (ATR)
- QURE 0.95
- ABUS 0.26
- MACD
- QURE -0.39
- ABUS 0.03
- Stochastic Oscillator
- QURE 3.13
- ABUS 55.33
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.